PTN

Palatin Technologies, Inc. (PTN) Q4 2026 Earnings Call Transcript

Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome Once-weekly injectable MC4R selective peptide agonist Phase 1 SAD/MAD study targeted to initiate in the first half of calendar 2027, with initial data targeted in the second half of 2027 Oral MC4R selective agonist Phase 1 SAD/MAD study targeted to initiate in the second half of calendar 2027, with initial data targeted in the first half of 2028 Multiple lipidated and non-lipidated peptide compounds demonstrated potent MC4R agonist activity but are not agonists at melanocortin 1 receptor (MC1R), supporting the potential to minimize or eliminate MC1R-mediated hyperpigmentation Fiscal 2026 collaboration and license revenue totaled $13.2 million, with approximately $9.4 million related to Boehringer Ingelheim and $3.8 million of non-cash license revenue under the Altanispac Labs agreement Cash and cash equivalents were $7.5 million as of June 30, 2026; additional funding will be required to continue advancing development programs and fund operations Conference call and webcast scheduled for September 28, 2026, at 11:00 a.m. ET PRINCETON, N.J.

Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired hypothalamic obesity and Bardet-Biedl syndrome, generated $71.3 million of global revenue during the second quarter of 2026, including $51.0 million in the United States and representing a 19% sequential quarter increase in global sales.

PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from the NYSE American.

Palatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcript